---
document_datetime: 2025-11-23 08:00:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/busilvex.html
document_name: busilvex.html
version: success
processing_time: 0.0980956
conversion_datetime: 2025-12-28 13:39:31.498066
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Busilvex

[RSS](/en/individual-human-medicine.xml/66845)

##### Withdrawn

This medicine's authorisation has been withdrawn

busulfan

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Busilvex](#news-on)
- [More information on Busilvex](#more-information-on-busilvex-804)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 January 2023, the European Commission withdrew the marketing authorisation for Busilvex (busulfan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pierre Fabre Medicament, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Busilvex was granted marketing authorisation in the EU on 9 July 2003 for use as a conditioning treatment prior to haematopoietic progenitor cell transplantation. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2008.

There are generic medicinal products of Busilvex authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Busilvex is updated to indicate that the marketing authorisation is no longer valid.

Busilvex : EPAR - Summary for the public

Reference Number: EMA/500878/2014

English (EN) (632.03 KB - PDF)

**First published:** 19/09/2008

**Last updated:** 04/08/2023

[View](/en/documents/overview/busilvex-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-41)

български (BG) (727.28 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/bg/documents/overview/busilvex-epar-summary-public_bg.pdf)

español (ES) (632.08 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/es/documents/overview/busilvex-epar-summary-public_es.pdf)

čeština (CS) (706.23 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/cs/documents/overview/busilvex-epar-summary-public_cs.pdf)

dansk (DA) (653.89 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/da/documents/overview/busilvex-epar-summary-public_da.pdf)

Deutsch (DE) (632.95 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/de/documents/overview/busilvex-epar-summary-public_de.pdf)

eesti keel (ET) (630.25 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/et/documents/overview/busilvex-epar-summary-public_et.pdf)

ελληνικά (EL) (729.13 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/el/documents/overview/busilvex-epar-summary-public_el.pdf)

français (FR) (633.45 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/fr/documents/overview/busilvex-epar-summary-public_fr.pdf)

hrvatski (HR) (652.57 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/hr/documents/overview/busilvex-epar-summary-public_hr.pdf)

italiano (IT) (652.81 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/it/documents/overview/busilvex-epar-summary-public_it.pdf)

latviešu valoda (LV) (704.46 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/lv/documents/overview/busilvex-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (657.75 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/lt/documents/overview/busilvex-epar-summary-public_lt.pdf)

magyar (HU) (699.44 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/hu/documents/overview/busilvex-epar-summary-public_hu.pdf)

Malti (MT) (708.29 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/mt/documents/overview/busilvex-epar-summary-public_mt.pdf)

Nederlands (NL) (632.68 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/nl/documents/overview/busilvex-epar-summary-public_nl.pdf)

polski (PL) (704.47 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/pl/documents/overview/busilvex-epar-summary-public_pl.pdf)

português (PT) (68.58 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/pt/documents/overview/busilvex-epar-summary-public_pt.pdf)

română (RO) (654.48 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/ro/documents/overview/busilvex-epar-summary-public_ro.pdf)

slovenčina (SK) (729.86 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/sk/documents/overview/busilvex-epar-summary-public_sk.pdf)

slovenščina (SL) (695.41 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/sl/documents/overview/busilvex-epar-summary-public_sl.pdf)

Suomi (FI) (631.13 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/fi/documents/overview/busilvex-epar-summary-public_fi.pdf)

svenska (SV) (634.02 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/sv/documents/overview/busilvex-epar-summary-public_sv.pdf)

## Product information

Busilvex : EPAR - Product Information

English (EN) (1001.13 KB - PDF)

**First published:** 19/09/2008

**Last updated:** 04/08/2023

[View](/en/documents/product-information/busilvex-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-804)

български (BG) (1.95 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/bg/documents/product-information/busilvex-epar-product-information_bg.pdf)

español (ES) (896.44 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/es/documents/product-information/busilvex-epar-product-information_es.pdf)

čeština (CS) (1.66 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/cs/documents/product-information/busilvex-epar-product-information_cs.pdf)

dansk (DA) (1008.12 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/da/documents/product-information/busilvex-epar-product-information_da.pdf)

Deutsch (DE) (1.02 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/de/documents/product-information/busilvex-epar-product-information_de.pdf)

eesti keel (ET) (972.62 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/et/documents/product-information/busilvex-epar-product-information_et.pdf)

ελληνικά (EL) (1.99 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/el/documents/product-information/busilvex-epar-product-information_el.pdf)

français (FR) (1023.19 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/fr/documents/product-information/busilvex-epar-product-information_fr.pdf)

hrvatski (HR) (1007.71 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/hr/documents/product-information/busilvex-epar-product-information_hr.pdf)

íslenska (IS) (937.3 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/is/documents/product-information/busilvex-epar-product-information_is.pdf)

italiano (IT) (978.84 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/it/documents/product-information/busilvex-epar-product-information_it.pdf)

latviešu valoda (LV) (1.57 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/lv/documents/product-information/busilvex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1016.01 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/lt/documents/product-information/busilvex-epar-product-information_lt.pdf)

magyar (HU) (1.53 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/hu/documents/product-information/busilvex-epar-product-information_hu.pdf)

Malti (MT) (1.6 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/mt/documents/product-information/busilvex-epar-product-information_mt.pdf)

Nederlands (NL) (887.39 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/nl/documents/product-information/busilvex-epar-product-information_nl.pdf)

norsk (NO) (890.3 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/no/documents/product-information/busilvex-epar-product-information_no.pdf)

polski (PL) (1.6 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/pl/documents/product-information/busilvex-epar-product-information_pl.pdf)

português (PT) (316.56 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/pt/documents/product-information/busilvex-epar-product-information_pt.pdf)

română (RO) (1010.13 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/ro/documents/product-information/busilvex-epar-product-information_ro.pdf)

slovenčina (SK) (1.55 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/sk/documents/product-information/busilvex-epar-product-information_sk.pdf)

slovenščina (SL) (1.55 MB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/sl/documents/product-information/busilvex-epar-product-information_sl.pdf)

Suomi (FI) (967.52 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/fi/documents/product-information/busilvex-epar-product-information_fi.pdf)

svenska (SV) (648.33 KB - PDF)

**First published:**

19/09/2008

**Last updated:**

04/08/2023

[View](/sv/documents/product-information/busilvex-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0035/G 01/02/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Busilvex Active substance busulfan International non-proprietary name (INN) or common name busulfan Therapeutic area (MeSH) Hematopoietic Stem Cell Transplantation Anatomical therapeutic chemical (ATC) code L01AB01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.

Busilvex following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.

Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

## Authorisation details

EMA product number EMEA/H/C/000472 Marketing authorisation holder

Pierre Fabre Medicament

Les Cauquillous 81500 - Lavaur France

Opinion adopted 19/03/2003 Marketing authorisation issued 09/07/2003 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Busilvex : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (812.78 KB - PDF)

**First published:** 19/09/2008

**Last updated:** 04/08/2023

[View](/en/documents/procedural-steps-after/busilvex-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Busilvex-H-C-PSUSA-00000464-201607 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/566488/2017

English (EN) (684.98 KB - PDF)

**First published:** 31/08/2017

**Last updated:** 04/08/2023

[View](/en/documents/scientific-conclusion/busilvex-h-c-psusa-00000464-201607-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Busilvex-H-C-472-II-019 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/550530/2014

English (EN) (3.76 MB - PDF)

**First published:** 29/09/2014

**Last updated:** 04/08/2023

[View](/en/documents/variation-report/busilvex-h-c-472-ii-019-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Busilvex

Adopted

Reference Number: EMA/CHMP/450097/2014

English (EN) (620.51 KB - PDF)

**First published:** 25/07/2014

**Last updated:** 04/08/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-busilvex_en.pdf)

Busilvex-H-C-PSUSA-0464 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

English (EN) (622.72 KB - PDF)

**First published:** 25/06/2014

**Last updated:** 04/08/2023

[View](/en/documents/scientific-conclusion/busilvex-h-c-psusa-0464-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Busilvex-H-C-472-A20-13 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/303399/2012

English (EN) (656.33 KB - PDF)

**First published:** 09/08/2012

**Last updated:** 04/08/2023

[View](/en/documents/variation-report/busilvex-h-c-472-a20-13-epar-assessment-report-article-20_en.pdf)

Busilvex-H-C-472-II-04 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (741.22 KB - PDF)

**First published:** 22/06/2006

**Last updated:** 04/08/2023

[View](/en/documents/scientific-discussion-variation/busilvex-h-c-472-ii-04-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Busilvex : EPAR - Scientific Discussion

English (EN) (947.63 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 04/08/2023

[View](/en/documents/scientific-discussion/busilvex-epar-scientific-discussion_en.pdf)

Busilvex : EPAR - Procedural steps taken before authorisation

English (EN) (645.2 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 04/08/2023

[View](/en/documents/procedural-steps/busilvex-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Busilvex

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2014) 25/07/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

[European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories) 16/02/2012

[European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-recommends-precautionary-recall-remaining-batch-vistide-manufactured-ben-venue-laboratories) 13/12/2011

[European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-further-interim-recommendations-dealing-shortcomings-quality-assurance-ben-venue-laboratories) 09/12/2011

[European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-interim-recommendations-deal-shortcomings-quality-assurance-ben-venue-laboratories) 22/11/2011

#### More information on Busilvex

This product is no longer an orphan medicine. It was [originally designated an orphan medicine](/en/medicines/human/orphan-designations/eu300011) on 29 December 2001. Busilvex was withdrawn from the Community register of orphan medicinal products in July 2013 at the end of the 10-year period of market exclusivity

Final recommendations on 12 centrally authorised medicines manufactured at Ben Venue Laboratories

Reference Number: EMA/106872/2012

English (EN) (188.14 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 22/02/2012

[View](/en/documents/medicine-qa/final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories_en.pdf)

Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories

Reference Number: EMA/946321/2011

English (EN) (71.91 KB - PDF)

**First published:** 13/12/2011

**Last updated:** 13/12/2011

[View](/en/documents/medicine-qa/questions-and-answers-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf)

**This page was last updated on** 04/08/2023

## Share this page

[Back to top](#main-content)